GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.
about
The impacts of single nucleotide polymorphisms in genes of cell cycle and NF-kB pathways on the efficacy and acute toxicities of radiotherapy in patients with nasopharyngeal carcinomaApoptosis induction by 13-acetoxyrolandrolide through the mitochondrial intrinsic pathway.STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth.IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity.Thymosin beta-4 regulates activation of hepatic stellate cells via hedgehog signaling.NF-κB, an active player in human cancers.Isolation and in vitro culture of rare cancer stem cells from patient-derived xenografts of pancreatic ductal adenocarcinoma.Discrete functions of GSK3α and GSK3β isoforms in prostate tumor growth and micrometastasis.Inhibition of glycogen synthase kinase-3β enhances cognitive recovery after stroke: the role of TAK1.GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer.Mining for Candidate Genes Related to Pancreatic Cancer Using Protein-Protein Interactions and a Shortest Path Approach.Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the PancreasA quinoxaline urea analog uncouples inflammatory and pro-survival functions of IKKβDifferential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis.The PRKD1 promoter is a target of the KRas-NF-κB pathway in pancreatic cancer.GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cellsGSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression.Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells.c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells.Measurement of protein kinase B activity in single primary human pancreatic cancer cells.Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cellsA new alpha in line between KRAS and NF-κB activation?Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passagesNF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.Exosomal lipids induce human pancreatic tumoral MiaPaCa-2 cells resistance through the CXCR4-SDF-1α signaling axis.Silencing of ECHDC1 inhibits growth of gemcitabine-resistant bladder cancer cells.DARPP-32 and t-DARPP promote non-small cell lung cancer growth through regulation of IKKα-dependent cell migrationDifferential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transitionResibufogenin suppresses transforming growth factor-β-activated kinase 1-mediated nuclear factor-κB activity through protein kinase C-dependent inhibition of glycogen synthase kinase 3
P2860
Q33648870-80BF534E-39C3-4FE5-8024-BAFF8F9A79DDQ33748016-B5310411-9327-49EE-9876-6D6226FC61F6Q33757027-FDB17C8D-1DB4-414A-898E-B4726A15EFBDQ33776852-9D311D87-CEEA-4575-80BE-1F421AB7359EQ33812502-C03EE560-0996-4B8F-BEF5-515D0A063996Q34138728-7BA6F244-9BAD-4C17-9221-E35E293969F1Q34788138-BAF9354D-AB5E-4515-A266-362C24657207Q35742439-D412DD8E-2068-49E3-BDA3-937D93CF68DDQ35773229-C8AAF904-2D44-4BF9-8E01-C6043DF8650CQ35980822-6C7E1EA3-9518-4FEF-B317-29563BCE9ECEQ36285296-2199E79C-4B32-4B54-92B7-223916B82FF4Q36378003-E6D7AC3F-15EF-4073-85DF-930B3E286D13Q36395993-FA20809C-7B22-4992-81BB-9FBA173592C9Q36814030-95EF1A66-7001-44A4-B172-A5BB8B981045Q37116160-469E30EB-B247-4741-A3A9-084CE036804FQ37271741-E8581BE6-665E-44B7-9769-A02AFD380F33Q37620336-88CF26A0-AAD2-45B7-B7F3-D6F9A8F14737Q38798496-F231C281-B9DE-401F-904A-133AE4D53699Q38922877-DCBD5CEB-713D-4ED0-A203-6DA4EE1B47DDQ38949421-315318EB-E7B7-446D-955D-1FEC0255E1B4Q39005983-2971500E-FA10-44A2-A894-ED5677ED15FFQ39011040-D24770F5-ED57-4496-8850-9734E2F5ADA6Q39142046-701A0085-BAE4-417C-921C-D5CC641F0F15Q39323428-F1D893AB-EFEC-4877-9997-B9A9E49B9979Q40465139-AECF531C-3BA3-4D6F-BB86-932374ECFAE6Q42042730-0D6B4D30-8C58-4F06-95AD-1922F4D62BFFQ42121985-5F0EFB7C-0AE0-4FA7-84A8-CE49B11BD4A0Q49213903-872AF966-0E28-4DCA-BE80-608F9D5616B3Q56815794-18409988-EAD4-4879-BAC9-A0F67E8816A8Q56942104-72BF7F3B-C30B-4019-A355-DE9B34543A16Q58701699-7D4F9125-EBF0-4EF7-9506-4511CFBE380C
P2860
GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
GSK-3α promotes oncogenic KRAS ...... ulation of noncanonical NF-κB.
@en
GSK-3α promotes oncogenic KRAS ...... ulation of noncanonical NF-κB.
@nl
type
label
GSK-3α promotes oncogenic KRAS ...... ulation of noncanonical NF-κB.
@en
GSK-3α promotes oncogenic KRAS ...... ulation of noncanonical NF-κB.
@nl
prefLabel
GSK-3α promotes oncogenic KRAS ...... ulation of noncanonical NF-κB.
@en
GSK-3α promotes oncogenic KRAS ...... ulation of noncanonical NF-κB.
@nl
P2093
P2860
P1433
P1476
GSK-3α promotes oncogenic KRAS ...... ulation of noncanonical NF-κB.
@en
P2093
Albert S Baldwin
Deepali Bang
Jen Jen Yeh
Meagan Ryan
Willie Wilson
P2860
P304
P356
10.1158/2159-8290.CD-12-0541
P577
2013-04-01T00:00:00Z